滋养层细胞表面抗原2在妇科恶性肿瘤中的研究进展  

Research Progress on Trophoblast Cell Surface Antigen 2 in Gynecological Malignant Tumors

作　　者：高红霞 魏芳[1] GAO Hongxia;WEI Fang(Second Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第二医院,山西太原030001

出　　处：《肿瘤学杂志》2025年第3期191-195,共5页Journal of Chinese Oncology

摘　　要：滋养层细胞表面抗原2(trophoblast cell surface antigen 2,Trop-2)是一种由肿瘤相关钙信号转导因子2基因编码的细胞表面糖蛋白,其结构包含前导序列、细胞外区域、跨膜区域和细胞内尾部区域,具有调节信号转导和影响细胞周期的功能。Trop-2在卵巢癌、宫颈癌和子宫内膜癌等妇科肿瘤中高表达,与肿瘤恶性程度、预后及转移风险相关。Trop-2通过激活信号通路促进肿瘤增殖和迁移,并具有干细胞样特性。Trop-2的抗体偶联药物戈沙妥珠单抗等已在临床试验中展现疗效,尤其针对Trop-2阳性的妇科肿瘤细胞。Trop-2作为治疗靶点的潜力巨大,为妇科恶性肿瘤提供了新的治疗选择和策略。Trophoblast cell surface antigen-2(Trop-2),encoded by the tumor-associated calcium signal transducer 2(TACSTD2) gene,is a cell surface glycoprotein consisting of a leader sequence,an extracellular domain,a transmembrane domain and an intracellular tail region.It functions as regulating signal transduction and influencing the cell cycle.Trop-2 is highly expressed in gynecological tumors such as ovarian cancer,cervical cancer,and endometrial cancer,and it is associated with tumor malignancy,prognosis,and metastasis risk.By activating signaling pathways,Trop-2 promotes tumor proliferation and migration and exhibits stem-cell-like properties.Antibody-drug conjugates(ADCs) targeting Trop-2,such as sacituzumab govitecan,have demonstrated efficacy in clinical trials,particularly against Trop-2-positive gynecological tumors.Trop-2 holds significant potential as a therapeutic target,offering new treatment options for gynecological malignancies.

关 键 词：滋养层细胞表面抗原2 妇科肿瘤 治疗靶点 

分 类 号：R737.3[医药卫生—肿瘤]